Detailed information on the studies selected for 2026 ASCO is as follows: Title: Sacituzumab tirumotecan (sac-TMT) plus pembrolizumab (P) versus pembrolizumab (P) as first-line treatment for ...

Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industrial chain, announced that a recent clinical case report on its self-developed novel Nectin-4 ADC ...

An AI model applied to pathology slides accurately predicts immunotherapy response in patients with metastatic non-small cell ...

In this video, Ursula A. Matulonis, MD, shares insight on the phase 3 KEYNOTE-B96 trial of pembrolizumab combination therapy vs. placebo in patients with PD-L1-positive, platinum-resistant ovarian ...

The cancer antigen therapy mRNA-4359 yielded a high rate of antitumor responses in combination with pembrolizumab (Keytruda) ...

Merck MRK announced that the FDA has accepted the two supplemental biologics license applications (sBLAs) seeking approval ...

The open-label, multi-center Phase Ⅱ clinical study is led by Professor Shen Lin of Beijing Cancer Hospital and is being conducted across multiple hospitals in China. The trial aims to evaluate the ...

Moderna, Revolution Medicines and Zymeworks record wins in melanoma, lung and breast cancers, while BeOne swings and misses ...

Balstilimab is a novel, fully human monoclonal immunoglobulin G4 (IgG4) designed to block PD-1 (programmed cell death protein 1) from interacting with its ligands PD-L1 and PD-L2. It has been ...

In a yearlong investigation led by the International Consortium of Investigative Journalists, reporters from more than 37 ...

Thai researchers unveil affordable immunotherapy cancer drug, aiming to cut costs and expand access for patients nationwide ...